Shiloh
Editor, Senior Moderator
Source: http://www.cidrap.umn.edu/news-perspective/2018/09/stewardship-resistance-scan-sep-25-2018
Stewardship / Resistance Scan for Sep 25, 2018
Antifungal stewardship; CARB-X call for open data
Filed Under:
Antimicrobial Stewardship
[h=3]Antifungal stewardship tied to an 89% drop in inappropriate prescribing[/h] A small single-center UK study has demonstrated that a diagnostics-driven antifungal stewardship (AFS) program was tied to an 89% drop in inappropriate prescribing, according to a study yesterday in the Journal of Antimicrobial Chemotherapy.
University of Manchester researchers assessed the AFS program at Wythenshawe Hospital, which has been developed over the past 8 years. It includes: (1) updating and clarifying antifungal guidelines, (2) involving and educating stewardship champions, (3) improving access to timely diagnostic testing, and (4) reducing unnecessary antifungal use.
The study included all patients who were prescribed micafungin for suspected or proven invasive candidiasis during 4-month audit periods in 2014 and 2016. The team reviewed prescriptions and patient records against AFS guidelines, as well as antifungal consumption and mortality data.
The investigators found that the number of patients treated for invasive candidiasis decreased from 39 in 2014 to 29 in 2016, mainly because of a reduction in patients initiated on antifungal therapy inappropriately?18 in 2014 and only 2 in 2016, an 89% drop. Antifungal therapy was stopped following negative biomarker results in 12 patients in 2014 and 10 patients in 2016. Crude mortality caused by proven or probable invasive candidiasis decreased from 45% to 19% (a 58% reduction), and antifungal consumption dropped by 49%.
Sep 24 J Antimicrob Chemother study
[h=3]CARB-X calls for open data sharing to spur antibiotic innovation[/h] Kevin Outterson, JD, the executive director of CARB-X, is calling on antibacterial researchers around the world to "help others learn from their setbacks" by openly sharing data from unsuccessful research in an effort to accelerate development to combat drug-resistant infections, CARB-X said in a news release yesterday.
As part of this effort, CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a public-private partnership, has reached an agreement with Achaogen to the non-exclusive transfer of compounds, scientific data, and assays to Forge Therapeutics from its innovative LpxC program. Achaogen announced last year that it had stopped the early development program over unexpected toxicity findings. Forge plans to review Achaogen's body of LpxC knowledge and apply the findings to its on-going LpxC research program.
Using a different chemistry approach than Achaogen, Forge is developing a novel class of antibiotics to treat gram-negative bacteria such as Pseudomonas aeruginosa and multidrug-resistant Enterobacteriaceae.
"Science is hard; most projects end for any number of reasons," Outterson said. "Typically, this knowledge and even the compounds themselves would be shuttered and locked away after a project is stopped. Given the economic realities of antibacterial research and the urgent need for new antibiotics, we need to adopt a more collaborative approach where it makes sense to do so."
CARB-X is encouraged by public data-sharing initiatives like the SPARK initiative announced by PEW Charitable Trusts last year and Wellcome Trust's Open Research initiative, launched in 2016, according to the release.
Sep 24 CARB-X news release
Stewardship / Resistance Scan for Sep 25, 2018
Antifungal stewardship; CARB-X call for open data
Filed Under:
Antimicrobial Stewardship
[h=3]Antifungal stewardship tied to an 89% drop in inappropriate prescribing[/h] A small single-center UK study has demonstrated that a diagnostics-driven antifungal stewardship (AFS) program was tied to an 89% drop in inappropriate prescribing, according to a study yesterday in the Journal of Antimicrobial Chemotherapy.
University of Manchester researchers assessed the AFS program at Wythenshawe Hospital, which has been developed over the past 8 years. It includes: (1) updating and clarifying antifungal guidelines, (2) involving and educating stewardship champions, (3) improving access to timely diagnostic testing, and (4) reducing unnecessary antifungal use.
The study included all patients who were prescribed micafungin for suspected or proven invasive candidiasis during 4-month audit periods in 2014 and 2016. The team reviewed prescriptions and patient records against AFS guidelines, as well as antifungal consumption and mortality data.
The investigators found that the number of patients treated for invasive candidiasis decreased from 39 in 2014 to 29 in 2016, mainly because of a reduction in patients initiated on antifungal therapy inappropriately?18 in 2014 and only 2 in 2016, an 89% drop. Antifungal therapy was stopped following negative biomarker results in 12 patients in 2014 and 10 patients in 2016. Crude mortality caused by proven or probable invasive candidiasis decreased from 45% to 19% (a 58% reduction), and antifungal consumption dropped by 49%.
Sep 24 J Antimicrob Chemother study
[h=3]CARB-X calls for open data sharing to spur antibiotic innovation[/h] Kevin Outterson, JD, the executive director of CARB-X, is calling on antibacterial researchers around the world to "help others learn from their setbacks" by openly sharing data from unsuccessful research in an effort to accelerate development to combat drug-resistant infections, CARB-X said in a news release yesterday.
As part of this effort, CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a public-private partnership, has reached an agreement with Achaogen to the non-exclusive transfer of compounds, scientific data, and assays to Forge Therapeutics from its innovative LpxC program. Achaogen announced last year that it had stopped the early development program over unexpected toxicity findings. Forge plans to review Achaogen's body of LpxC knowledge and apply the findings to its on-going LpxC research program.
Using a different chemistry approach than Achaogen, Forge is developing a novel class of antibiotics to treat gram-negative bacteria such as Pseudomonas aeruginosa and multidrug-resistant Enterobacteriaceae.
"Science is hard; most projects end for any number of reasons," Outterson said. "Typically, this knowledge and even the compounds themselves would be shuttered and locked away after a project is stopped. Given the economic realities of antibacterial research and the urgent need for new antibiotics, we need to adopt a more collaborative approach where it makes sense to do so."
CARB-X is encouraged by public data-sharing initiatives like the SPARK initiative announced by PEW Charitable Trusts last year and Wellcome Trust's Open Research initiative, launched in 2016, according to the release.
Sep 24 CARB-X news release